Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry.
Lorenzo AzzaliniGurpreet S JohalUsman BaberJeffrey BanderPedro R MorenoLucas BaziVishal KapurNitin BarmanAnnapoorna S KiniSamin K SharmaPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Although Impella-supported patients suffer a higher incidence of periprocedural adverse events (partially linked to more aggressive PCI), the incidence of one-year MACE was similar between the Impella and control group.
Keyphrases
- percutaneous coronary intervention
- end stage renal disease
- acute myocardial infarction
- st segment elevation myocardial infarction
- coronary artery disease
- acute coronary syndrome
- extracorporeal membrane oxygenation
- st elevation myocardial infarction
- antiplatelet therapy
- risk factors
- chronic kidney disease
- ejection fraction
- newly diagnosed
- left ventricular assist device
- coronary artery bypass grafting
- prognostic factors
- atrial fibrillation
- peritoneal dialysis
- type diabetes
- skeletal muscle
- adipose tissue
- insulin resistance
- metabolic syndrome
- glycemic control
- weight loss